Remove 2040 Remove Clinical Trials Remove Treatment
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In October the Company announced the issuance of U.S. and Arjun Chanmugam, M.D.,

article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. Dr. Chapman Bio. About MYMD-1.